Jumat, 11 Mei 2018

VR MED platform


VR MED is the first medical device in the world that uses VR technology for a variety of uses. It has a similar success not only in ophthalmology but also in neurology and rehabilitation. All you need for the transformation is to enter the required software and configure the system. It is not necessary to replace the device itself. Only one set of equipment covers most of the clinic's needs with virtual reality technology.

Description of the platform and its need for development of VR MED
  1. Data storage, transportation, exchange and sales.
  2. Assistance for the development of new software solutions that use headphones: approval, test, introduction in the market through an internal platform for the acquisition of investments.
  3. Sales of new successful software solutions to the medical center.

Sale token
  • About Token VRMD
  • Token: ERC Protocol 20
  • Quantity: 30,000,000 Token
  • Price: 0.25 USD = 1 Token VRMD
  • Buy with: BTC, ETH, USD
Details
  • Hardcover: $ 5,000,000
  • Soft hat: $ 1,000,000
Token distribution and budget:
  • 20,000,000 VRMD - Crowd of sales
  • 4,000,000 VRMD - Team, Bounty, Marketing
  • 6,000,000 VRMD - Backup
All unsold tokens will be burned
 Street map

=> Before ICO
  • 06.2016

From the development of VR headsets and programming that are suitable for medical use.
  • 12.16 - 02.17

Patents are granted in Russia.
From the process of receiving international patents
  • 02.17 to 04.17

Creation of equipment and software models for screening for the early detection of glaucoma and other conditions with peripheral vision defects.
Successful experimental results at the Eye Disease Institute of the Russian Academy of Sciences
  • 04.17

Participation in international presentations in Lisbon and Bahrain. Device recognition
  • 05-17-2017

A successful approval process for tools and software at FH Aachen University of Applied Sciences
  • 07.17-10.17

Development of the Alpha version of the device, with the ability to provide solutions in ophthalmology (peripheral vision measurement, diagnosis of glaucoma markers).

=> After the ICO
  • 03.18 - 06.18

Development of the final version of the device
(technical use and fine tuning), construction improvements
  • 06.18 - 08.18

ISO 12866-2011 standard. Development of industrial design
  • 08.18 to 12.18

"Perimetral" software certification: creation of a universal design for the diagnosis of various visual functions (through the initial diagnosis of glaucoma and other peripheral vision defects)
  • 04.18 - 09.18

Entry into the world market: completion of the approval process in Indian and Chinese clinics; got the ISO international certification
  • 05.18 - 07.19

Upload user data to the platform. Distribution of devices in the EU, Russia and Asia;
The launch of a decentralized platform;
The functional perimeter is 100% of the "gold standard" in the ophthalmic diagnosis
  • 05.18 - 07.19

Functions of the widening device to include the use in neurology and rehabilitation.

Tim
  1. Levon Grigoryan - CEO, co-founder, author of the patent
  2. Alex Sundukov - COO, SAP, HP, PwC, Philips
  3. Ilya Panenkov - Leading developers in medical business
  4. Dmitriy Mikhailov - Investment Director, co-founder of Aktivo, MTS
  5. Alexey Ermolaev - Medical Leader, MD, Co-Founder, Patent Writer
  6. Grigor Grigoryan - CTO, co-founder, author of the patent
  7. Aleksandr Zayanchukovskiy - Lead Design Engineer, Model Specialist
  8. Denis Ovod - Virtual Reality Developer, Graphics Programmer, Red Machine LLC, WELL, Diamond Scent Ltd, BioLink
  9. Anton Shokurov - Lead Engineer, Mathematician, Developer Algorithm
  10. Andrey Pravdivtsev - Optical designer, modeling of optical systems
  11. Kseniia Deina - Manager SMM
  12. Alex Fominyh - Senior Engineer
  13. Ekaterina Gromyko - Public Relations and Marketing Specialist
  14. Ekaterina Medvedeva - Marketing Director

Adviser
  1. Ina Glueck
  2. Konstantin Kotlyar
  3. Alexey Antonov
For more information, CLICK on its official website below:

Tidak ada komentar:

Posting Komentar